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The Editorial on the Research Topic
Molecules Balancing Immunological Surveillance against Cancer and Autoimmune Diseases
The innate and the adaptive immune systems work in concert to deal with pathologies introduced by 
internal and external factors (e.g., viruses, bacteria, and fungi) – some of which may be associated 
with the development of autoimmune and cancerous cells. Mechanistically, there are internal factors 
that are responsible for the hypo- and hyperfunction of immune tolerance apparatus. Consequently, 
it could lead to the development of autoimmune diseases and malignancies, respectively. In the last 
decade, the study of cancer and autoimmunity suggested that these two entities might reflect two 
opposed extreme end-points of an immune response spectrum. Accordingly, the overexpression of 
certain molecules could result in malignancies, whereas deficient expression of the same molecules 
could lead to the development of autoimmune diseases.
Two journals, Frontiers in Immunology and Frontiers in Oncology, participated in this special 
issue in an attempt to gain the prospective of professionals in both fields of autoimmunity and cancer, 
hoping to identify molecules and factors that possess dual roles with opposing effects on autoim-
mune diseases and cancer.
E3 ligase Cbl-b, as reviewed by Lutz-Nicoladoni et al., is central in the balance of activating and 
inhibitory inputs to immune cells. Specifically, Cbl-b negatively regulates activation signals through 
antigen or pattern recognition receptors and costimulatory molecules. Although cblb-deficient 
immune cells display lower activation thresholds and cblb knockout mice spontaneously develop 
autoimmunity and are highly susceptible to experimental autoimmunity, the increased activation 
potential of cblb-deficient cells renders them more potent to fight against malignancies or infections.
In the study of multiple sclerosis (MS), Kaushansky and Ben-Nun, report that the allele DQB1*06:02 
shown previously to be a disease-modifying allele, also plays a role as a disease-predisposing allele. 
They review a novel “humanized” model of MS-like disease, in which autoimmunity against myelin 
may be driven by a pathogenic HLA-DQ expression. This model also supports an additional target 
autoantigen, e.g., myelin-associated oligodendrocytic basic protein (MOBP) in the pathogenesis of MS.
Haque et al. summarize the utilization of regulatory T cells (Treg cells) in treating rheumatoid 
arthritis (RA). Because Foxp3 can be polyubiquitinated, they show that the expression of Foxp3 in 
T cells can be facilitated through Foxp3 ubiquitination. Ubiquitin-specific-processing protease 7 
(USP7) is an active enzyme in Treg cells, which may be associated with Foxp3, and leads to its deu-
biquitination. By contrast, diminished function of USP7 results in a decreased function of Treg cells.
In RA, Treg cells do not possess normal immune suppressive activity, although they can be found 
in the joints of the patients. It is explained, in part, by the elevated levels of TNF-α within the inflamed 
synovium and the joint fluid, which may lead to Foxp3 phosphorylation, thereby interfering with the 
suppressive capacities of Treg cells. Recent studies demonstrated that induced pluripotent stem cell 
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(iPSC) can be reprogramed to constitute a source for functional 
CD4+ Treg cells or CD8+ cytotoxic T lymphocytes. The adoptive 
transfer of the latter cells may be used for immunotherapy of 
autoimmune arthritis and cancers. Hence, generation of antigen-
specific Foxp3+ Treg cells from stem cells, such as iPSCs, may open 
a new area in Treg cell-based immunotherapy in transplantation 
and autoimmune disorders.
Manjili et  al. describes the evolution of myeloid regulatory 
cells (Mregs). These cells suppress (through direct and indirect 
mechanisms) the host’s anti-tumor immune responses in favor of 
the tumor. By contrast, the ability of Mregs to limit and modulate 
Th1 responses or support a skewed Th2 immunity could be ben-
eficial during parasitic and helminth infections. In addition, the 
immunoregulatory functions of Mregs on Th17 differentiation 
and inflammation were demonstrated in experimental autoim-
mune encephalomyelitis (EAE). In this model, treatment with 
gemcitabine that depleted Mregs led to a reduction in Th17 cells, 
IL-17A, and IL-1β in the lymphoid tissues and spinal cord and to 
a substantial decrease in the severity of EAE. In addition, Mregs 
were shown to induce Th17 differentiation in tumor-bearing 
mice and in patients with ovarian cancer. Also, Mregs’ levels 
correlated the levels of Th17 cells or IL-17 production in patients 
with gastrointestinal cancer. Because of the association observed 
between inflammation, tumorigenesis, and the progression of 
autoimmune diseases, these proinflammatory cells may repre-
sent a pivotal pathogenic factor in the spectrum of cancer and 
autoimmunity.
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